Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Erin W. Meermeier, Kirsten Pfeffer, Caleb K. Stein, Meaghen E. Sharik, Megan T. Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (25): 3072–3085.

https://doi.org/10.1182/blood.2025029215

Published: 2025

Includes: Supplemental data

Journal Articles

Reprogramming glutamine metabolism enhances BCMA -CAR T-cell fitness and therapeutic efficacy in multiple myeloma

Blood (2025) 146 (24): 2931–2944.

https://doi.org/10.1182/blood.2024027496

Published: 2025

Includes: Supplemental data

Journal Articles

Retention of immunosuppressive C1Q macrophages following therapeutic interventions imparts negative outcomes across human multiple myeloma studies

Caleb Stein, Erin Meermeier, Taxiarchis Kourelis, Joselle Cook, Yuliza Shotts, Yuan Zhu, Chang-Xin Shi, Kirsten Pfeffer, Meaghen Sharik, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 7481.

https://doi.org/10.1182/blood-2025-7481

Published: 2025

Journal Articles

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler, Erin Meermeier, Antonia Schach, Vera Thiel, Tim Wagner, Niklas Kehl, Stefanie Huhn, Alexander Brobeil, Carsten Müller-Tidow, P. Leif Bergsagel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Marta Chesi, Marc Raab, Niels Weinhold, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2025-3951

Published: 2025

Journal Articles

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Lorenzo Lindo, Kevin Hay, Erin Meermeier, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2025-5728

Published: 2025

Journal Articles

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2025-2139

Published: 2025

Journal Articles

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Yusuke Yamashita, Jonathan Patton, Yuliza Shotts, Megan Du, Meaghen Sharik, Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Caleb Stein, Erin Meermeier, Marta Chesi, Lanbo Xiao, Arul Chinnaiyan, Benjamin Barwick, P. Leif Bergsagel

Blood (2025) 146 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2025-2138

Published: 2025

Journal Articles

Alternate dosing schedules of BCMA-directed T cell engagers display altered pathways of relapse in syngeneic vk*MYC multiple myeloma

Erin Meermeier, Caleb Stein, Meaghen Sharik, Megan Du, Yuan Zhu, Chang-Xin Shi, Kirsten Pfeffer, Keith Abayasiriwardana, Timothy Fisher, Kristin Bompiani-Myers, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 913.

https://doi.org/10.1182/blood-2025-913

Published: 2025

Journal Articles

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Blood (2024) 144 (Supplement 1): 671.

https://doi.org/10.1182/blood-2024-202224

Published: 2024

Journal Articles

Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Erin W Meermeier, Caleb K Stein, Meaghen Sharik, Megan Du, Yuan Xiao Zhu, Chang-Xin Shi, Yuliza Shotts, Maria Josic, Keith Abayasiriwardana, Natalie Bezman, Timothy Fisher, Kristin Bompiani-Myers, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 358.

https://doi.org/10.1182/blood-2024-210917

Published: 2024

Journal Articles

Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN + Preclinical Model of Multiple Myeloma

Erin W Meermeier, Meaghen Sharik, Megan Du, Caleb K Stein, Yuan Xiao Zhu, Chang-Xin Shi, Yuliza Shotts, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 356.

https://doi.org/10.1182/blood-2024-212225

Published: 2024

Journal Articles

Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy

Caleb K Stein, Erin W Meermeier, Yuliza Shotts, Yuan Xiao Zhu, Chang-Xin Shi, Kirsten Pfeffer, Megan Du, Meaghen Sharik, Leif Bergsagel, Marta Chesi

Blood (2024) 144 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2024-212331

Published: 2024

Journal Articles

UnSETtling energy dependence of t(4;14) MM

P. Leif Bergsagel, Marta Chesi

Blood (2024) 144 (3): 244–245.

https://doi.org/10.1182/blood.2024024871

Published: 2024

Journal Articles

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Laura Lucia Cogrossi, Matteo Grioni, Paola Zordan, Benedetta Mattorre, Marco Lorenzoni, Greta Meregalli, Anna Policastro, Roberto Ferrarese, Nicola Clementi, Sofia Sisti, Nicasio Mancini, Marta Chesi, P. Leif Bergsagel, Matteo Bellone

Blood (2023) 142 (Supplement 1): 754.

https://doi.org/10.1182/blood-2023-180145

Published: 2023

Journal Articles

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Sinto Sebastian Chirackal, Taro Hitosugi, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2023-189785

Published: 2023

Journal Articles

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Yan Cheng, Fumou Sun, Wancheng Guo, Hongwei Xu, Prasanth Viswanathan, Mark Manzano, Eric Siegel, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Marta Chesi, P. Leif Bergsagel, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3309.

https://doi.org/10.1182/blood-2023-187001

Published: 2023

Journal Articles

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

Lorenzo Lindo, Erin Meermeier, Lauren H Wilkinson, Silvia Selleri, Mehdi Arbabi Ghahroudi, Scott McComb, P. Leif Bergsagel, Marta Chesi, Laura Evgin, Daniel D Waller, Kevin A Hay

Blood (2023) 142 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2023-178821

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Reprogramming glutamine metabolism enhances BCMA -CAR T-cell fitness and therapeutic efficacy in multiple myeloma

Retention of immunosuppressive C1Q macrophages following therapeutic interventions imparts negative outcomes across human multiple myeloma studies

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Alternate dosing schedules of BCMA-directed T cell engagers display altered pathways of relapse in syngeneic vk*MYC multiple myeloma

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN + Preclinical Model of Multiple Myeloma

Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy

UnSETtling energy dependence of t(4;14) MM

Exploiting the Gut Microbiota to Boost Immunotherapy and Switch the Trajectory of Multiple Myeloma

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma

Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only